Sequentify

Ophir is a serial entrepreneur with over 20 years of operational and technology-driven experience. He was the CEO and founder of Jungo Connectivity, a spinoff from Cisco that develops ground-breaking computer-vision automotive driver monitoring products, and led its IPO in 2021. In his past, he was a GM at Jungo (acquired by NDS $107M) and an executive at NDS (acquired by Cisco, $5B). He was also the founder and CEO of Mathtools, a company that specialized in MATLAB compilers and related technologies (acquired by MathWorks). He holds a BSc in electrical engineering (summa cum laude) from the Technion – Israel Institute of Technology and is a world-class bridge player, holding international wins and often representing Israel in international competitions.

Tamir is a molecular biology and genomics expert with a research background of more than 15 years and more than 10 years background in next generation sequencing technologies. Tamir has gained experience in various scientific fields including plant science, synthetic biology, and single cell genomics. He acquired his BSc degree in biotechnology from Bar-Ilan University and his MSc and PhD degrees working in the laboratory of Prof. Ehud Shapiro from the Weizmann Institute of Science. As a research associate in the laboratory of Liran Shlush at the Weizmann Institute of Science, Tamir developed molecular biology assays and lab automation capabilities for the clinical research practice. In his free time Tamir loves traveling in the company of his wife and three kids.

Following a bachelor’s degree in traditional Chinese medicine from the Hebrew University of Jerusalem, Tom became an expert in the fields of leukemia and bioprospecting. He acquired his MSc and PhD degrees in Taiwan. During this time he conducted population-based epidemiologic studies, gained expertise in basic-science immunologic methods, as well as designed and coordinated clinical studies in hospital settings. As a postdoctoral fellow at the Weizmann Institute of Science, he conducted drug-development research using state-of-the-art high-throughput methodologies and numerous next-generation sequencing technologies. Tom is also fully fluent in Mandarin Chinese and an avid mountain hiker.

Liran is a senior scientist at the Weizmann Institute of Science, Department of Immunology and a visiting hematologist at the Ontario Cancer Institute, Princess Margaret Cancer Center, and the hematology department Rambam healthcare campus, Haifa, Israel. Dr. Shlush’s research and clinical activities are focused on the early stages of leukemia. Dr. Shlush and colleagues identified the human pre-leukemic stem cells 1,2 and proved that a latent period in which stem cell acquire mutations exists.